Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer

A. T. Baron, J. A. Wilken, D. E. Haggstrom, S. T. Goodrich, Nita Jane Maihle

Research output: Contribution to journalReview article

29 Citations (Scopus)

Abstract

Signal transduction pathways regulated by the EGFR/ERBB/HER proto-oncogene family and receptor tyrosine kinases encoded by these genes are known to become dysregulated during cellular transformation and carcinogenesis. Consequently, biologically targeted antibodies and tyrosine kinase inhibitors directed toward EGFR/ErbB1/HER1 (eg, cetuximab, erlotinib and gefitinib) and ErbB2/HER2 (eg, trastuzumab), and more recently toward ErbB3/HER3 and ErbB4/HER4, are being investigated as therapeutic agents for treating patients with EGFR/ERBB/HER proto-oncogene-driven malignancies. The accurate selection of patients who will respond efficaciously to these agents a priori is a medical challenge. Understanding the clinical utility of soluble EGFR/ErbB/HER (ie, sEGFR/sErbB/sHER) isoforms, which are present in circulatory fluids, as theragnostic cancer biomarkers is an emerging area of contemporary biomedical investigation. This feature article reviews the literature regarding the clinical utility of serum sEGFR/sErbB1/sHER1 in breast, lung and ovarian cancer, and discusses the potential role of sEGFR in predicting and monitoring therapeutic responsiveness, as well as disease recurrence, and/or predicting disease outcome in patients treated with specific small-molecule, hormonal or biotherapeutic drug regimens. Well-designed translational research studies are needed to validate sEGFR as a theragnostic biomarker further and to achieve routine clinical implementation.

Original languageEnglish (US)
Pages (from-to)302-308
Number of pages7
JournalIDrugs
Volume12
Issue number5
StatePublished - May 1 2009
Externally publishedYes

Fingerprint

Proto-Oncogenes
Ovarian Neoplasms
Lung Neoplasms
Biomarkers
Breast Neoplasms
Translational Medical Research
Receptor Protein-Tyrosine Kinases
Proxy
Tumor Biomarkers
Serum
Protein-Tyrosine Kinases
Patient Selection
Signal Transduction
Protein Isoforms
Carcinogenesis
Recurrence
Antibodies
Therapeutics
Pharmaceutical Preparations
Genes

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology
  • Drug Discovery

Cite this

Baron, A. T., Wilken, J. A., Haggstrom, D. E., Goodrich, S. T., & Maihle, N. J. (2009). Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer. IDrugs, 12(5), 302-308.

Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer. / Baron, A. T.; Wilken, J. A.; Haggstrom, D. E.; Goodrich, S. T.; Maihle, Nita Jane.

In: IDrugs, Vol. 12, No. 5, 01.05.2009, p. 302-308.

Research output: Contribution to journalReview article

Baron, AT, Wilken, JA, Haggstrom, DE, Goodrich, ST & Maihle, NJ 2009, 'Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer', IDrugs, vol. 12, no. 5, pp. 302-308.
Baron AT, Wilken JA, Haggstrom DE, Goodrich ST, Maihle NJ. Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer. IDrugs. 2009 May 1;12(5):302-308.
Baron, A. T. ; Wilken, J. A. ; Haggstrom, D. E. ; Goodrich, S. T. ; Maihle, Nita Jane. / Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer. In: IDrugs. 2009 ; Vol. 12, No. 5. pp. 302-308.
@article{1ae888d0fa854720b0c616d8fb48e643,
title = "Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer",
abstract = "Signal transduction pathways regulated by the EGFR/ERBB/HER proto-oncogene family and receptor tyrosine kinases encoded by these genes are known to become dysregulated during cellular transformation and carcinogenesis. Consequently, biologically targeted antibodies and tyrosine kinase inhibitors directed toward EGFR/ErbB1/HER1 (eg, cetuximab, erlotinib and gefitinib) and ErbB2/HER2 (eg, trastuzumab), and more recently toward ErbB3/HER3 and ErbB4/HER4, are being investigated as therapeutic agents for treating patients with EGFR/ERBB/HER proto-oncogene-driven malignancies. The accurate selection of patients who will respond efficaciously to these agents a priori is a medical challenge. Understanding the clinical utility of soluble EGFR/ErbB/HER (ie, sEGFR/sErbB/sHER) isoforms, which are present in circulatory fluids, as theragnostic cancer biomarkers is an emerging area of contemporary biomedical investigation. This feature article reviews the literature regarding the clinical utility of serum sEGFR/sErbB1/sHER1 in breast, lung and ovarian cancer, and discusses the potential role of sEGFR in predicting and monitoring therapeutic responsiveness, as well as disease recurrence, and/or predicting disease outcome in patients treated with specific small-molecule, hormonal or biotherapeutic drug regimens. Well-designed translational research studies are needed to validate sEGFR as a theragnostic biomarker further and to achieve routine clinical implementation.",
author = "Baron, {A. T.} and Wilken, {J. A.} and Haggstrom, {D. E.} and Goodrich, {S. T.} and Maihle, {Nita Jane}",
year = "2009",
month = "5",
day = "1",
language = "English (US)",
volume = "12",
pages = "302--308",
journal = "IDrugs : the investigational drugs journal",
issn = "1369-7056",
publisher = "Current Drugs Ltd.",
number = "5",

}

TY - JOUR

T1 - Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer

AU - Baron, A. T.

AU - Wilken, J. A.

AU - Haggstrom, D. E.

AU - Goodrich, S. T.

AU - Maihle, Nita Jane

PY - 2009/5/1

Y1 - 2009/5/1

N2 - Signal transduction pathways regulated by the EGFR/ERBB/HER proto-oncogene family and receptor tyrosine kinases encoded by these genes are known to become dysregulated during cellular transformation and carcinogenesis. Consequently, biologically targeted antibodies and tyrosine kinase inhibitors directed toward EGFR/ErbB1/HER1 (eg, cetuximab, erlotinib and gefitinib) and ErbB2/HER2 (eg, trastuzumab), and more recently toward ErbB3/HER3 and ErbB4/HER4, are being investigated as therapeutic agents for treating patients with EGFR/ERBB/HER proto-oncogene-driven malignancies. The accurate selection of patients who will respond efficaciously to these agents a priori is a medical challenge. Understanding the clinical utility of soluble EGFR/ErbB/HER (ie, sEGFR/sErbB/sHER) isoforms, which are present in circulatory fluids, as theragnostic cancer biomarkers is an emerging area of contemporary biomedical investigation. This feature article reviews the literature regarding the clinical utility of serum sEGFR/sErbB1/sHER1 in breast, lung and ovarian cancer, and discusses the potential role of sEGFR in predicting and monitoring therapeutic responsiveness, as well as disease recurrence, and/or predicting disease outcome in patients treated with specific small-molecule, hormonal or biotherapeutic drug regimens. Well-designed translational research studies are needed to validate sEGFR as a theragnostic biomarker further and to achieve routine clinical implementation.

AB - Signal transduction pathways regulated by the EGFR/ERBB/HER proto-oncogene family and receptor tyrosine kinases encoded by these genes are known to become dysregulated during cellular transformation and carcinogenesis. Consequently, biologically targeted antibodies and tyrosine kinase inhibitors directed toward EGFR/ErbB1/HER1 (eg, cetuximab, erlotinib and gefitinib) and ErbB2/HER2 (eg, trastuzumab), and more recently toward ErbB3/HER3 and ErbB4/HER4, are being investigated as therapeutic agents for treating patients with EGFR/ERBB/HER proto-oncogene-driven malignancies. The accurate selection of patients who will respond efficaciously to these agents a priori is a medical challenge. Understanding the clinical utility of soluble EGFR/ErbB/HER (ie, sEGFR/sErbB/sHER) isoforms, which are present in circulatory fluids, as theragnostic cancer biomarkers is an emerging area of contemporary biomedical investigation. This feature article reviews the literature regarding the clinical utility of serum sEGFR/sErbB1/sHER1 in breast, lung and ovarian cancer, and discusses the potential role of sEGFR in predicting and monitoring therapeutic responsiveness, as well as disease recurrence, and/or predicting disease outcome in patients treated with specific small-molecule, hormonal or biotherapeutic drug regimens. Well-designed translational research studies are needed to validate sEGFR as a theragnostic biomarker further and to achieve routine clinical implementation.

UR - http://www.scopus.com/inward/record.url?scp=67649371211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649371211&partnerID=8YFLogxK

M3 - Review article

VL - 12

SP - 302

EP - 308

JO - IDrugs : the investigational drugs journal

JF - IDrugs : the investigational drugs journal

SN - 1369-7056

IS - 5

ER -